STAAR Surgical Appoints Deborah Andrews as EVP & CFO to Drive EVO ICL Growth

STAAR Surgical appoints Deborah Andrews as EVP & CFO to lead financial strategy and growth for EVO ICL phakic IOLs, strengthening NASDAQ: STAA leadership.

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs and maker of the EVO family of Implantable Collamer® Lenses (EVO ICL™), has appointed Deborah Andrews as Executive Vice President and Chief Financial Officer. The leadership move reinforces STAAR’s commitment to accelerating growth in vision correction and strengthening financial oversight as the company scales globally.

As EVP and CFO, Deborah Andrews will oversee financial strategy, reporting, and investor relations for STAAR Surgical. Her role will be central to supporting the EVO ICL product family’s expansion in existing and emerging markets, optimizing capital allocation, and ensuring robust financial governance. The appointment highlights STAAR’s focus on combining clinical innovation in phakic IOLs with disciplined financial leadership to advance long-term shareholder value.

Deborah Andrews brings extensive experience in corporate finance, strategic planning, and operational leadership. She is expected to partner with STAAR’s executive team to refine financial forecasting, streamline reporting processes, and support commercialization initiatives for implantable collamer lenses. Her stewardship will also play a key role in communicating the company’s vision to investors and stakeholders as STAAR navigates market opportunities in vision correction technology.

The EVO ICL continues to be a leading alternative for patients seeking vision correction through phakic IOLs. STAAR’s focus on innovation in the EVO family has driven clinical adoption and differentiated the company in the ophthalmic device market. By strengthening financial and operational leadership, STAAR aims to accelerate access to EVO ICL solutions while maintaining high standards of product quality and regulatory compliance.

Investors and industry observers will watch how this leadership change supports STAAR’s strategic goals, including revenue growth, international expansion, and enhanced shareholder communications. With Deborah Andrews in the CFO role, the company is positioned to align financial planning with its clinical and commercial milestones for the EVO ICL portfolio.

STAAR Surgical’s announcement underscores the company’s dual focus on cutting-edge vision correction technology and strong corporate governance. As STAAR continues to develop and promote implantable collamer lenses, the new financial leadership is intended to support sustainable growth and reinforce the company’s standing on NASDAQ: STAA.

Back